How to Get Praluent (Alirocumab) in Alabama

What Is Praluent and Why Alabama Patients Are Prescribed It

Praluent (alirocumab) is a fully human monoclonal antibody that blocks PCSK9, the protein responsible for degrading LDL receptors in the liver. Fewer active PCSK9 molecules means more LDL receptors available to clear circulating LDL-C from the bloodstream. The drug is FDA-approved for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond what maximally tolerated statin therapy provides [1].

Alabama has one of the highest rates of cardiovascular disease mortality in the United States. According to the CDC, heart disease remains the leading cause of death in Alabama, accounting for roughly 25% of all state deaths annually [2]. That disease burden translates directly into a large pool of patients who may qualify for PCSK9 inhibitor therapy yet face significant access barriers related to cost and prior authorization complexity.

Alirocumab is administered as a subcutaneous injection either 75 mg or 150 mg every two weeks, or 300 mg once monthly. In the key ODYSSEY LONG TERM trial (N=2,341), the 150 mg every-two-weeks dose reduced LDL-C by a mean of 61% from baseline at week 24, compared with a 0.8% reduction in the placebo group (P<0.0001) [3]. A dose of 75 mg every two weeks, with optional uptitration to 150 mg, is the standard starting strategy for most patients and is consistent with the 2018 AHA/ACC Guideline on the Management of Blood Cholesterol [4].

The drug requires refrigerated storage between 36°F and 77°F (2°C to 25°C). Patients who travel or have limited refrigerator access should discuss storage logistics with their dispensing pharmacy before the first shipment arrives.

How to Get a Praluent Prescription in Alabama

Getting a Praluent prescription in Alabama requires a licensed prescriber who has reviewed your cardiovascular history, current lipid panel, and statin trial record. The process is straightforward once those three elements are documented.

Step 1. Establish or confirm your diagnosis. A prescriber must document either HeFH or established ASCVD (prior MI, stroke, or peripheral arterial disease) to support both the clinical decision and any prior authorization submission. Genetic testing for HeFH is not required for a clinical diagnosis under the Dutch Lipid Clinic Network criteria [5], though some insurers ask for it.

Step 2. Obtain a recent lipid panel. Most commercial payers require an LDL-C drawn within the past six to twelve months showing values above their threshold (commonly LDL-C above 70 mg/dL for ASCVD patients and above 100 mg/dL for HeFH patients on maximally tolerated statin therapy) before they will authorize PCSK9 inhibitor use [6].

Step 3. Document statin history. Prior authorization forms universally ask for the names, doses, and durations of at least two statins tried, plus documentation of intolerance or inadequate response. A record showing trials of atorvastatin 40-80 mg and rosuvastatin 20-40 mg for at least 4-8 weeks each, with LDL-C values and any adverse events noted, satisfies most Alabama commercial payer criteria.

Step 4. Choose your prescriber. Cardiologists, lipidologists, endocrinologists, internal medicine physicians, nurse practitioners, and physician assistants are all legally authorized to prescribe Praluent in Alabama (see the prescriber scope section below). Telehealth providers licensed in Alabama can prescribe after a thorough synchronous video visit that meets the Alabama Board of Medical Examiners standard of care requirements [7].

Step 5. Submit prior authorization. Your prescriber's office typically handles this. Expect a 5-15 business day decision timeline for commercial plans. If denied, appeal immediately with additional clinical documentation.

Step 6. Use the specialty pharmacy designated by your insurer. Praluent ships cold from specialty pharmacies such as CVS Specialty, Walgreens Specialty, or Accredo. First-fill processing after PA approval averages 3-7 business days.

Telehealth Prescribing for Praluent in Alabama

Alabama allows telehealth prescribing of Praluent. Patients may consult a licensed Alabama telehealth provider from any location within state lines, including rural counties where in-person lipidologists are scarce.

Under the Alabama Board of Medical Examiners Rule 540-X-9, a valid prescriber-patient relationship may be established via synchronous audio-video technology, provided the provider takes an adequate medical history, reviews relevant records, and follows the same standard of care that would apply in an in-person visit [7]. Prescribing Praluent via asynchronous messaging or questionnaire alone does not meet that standard and should be avoided.

The practical advantage of telehealth for Alabama patients is geographic reach. Alabama's Black Belt region and rural northern counties have limited access to cardiologists. A 2021 analysis published in the Journal of the American Heart Association found that patients in rural areas were 32% less likely to receive guideline-directed lipid-lowering therapy than urban patients [8]. Telehealth closes some of that gap by connecting rural Alabama patients to providers who can prescribe and manage PCSK9 inhibitor therapy without requiring a four-hour round trip.

Before a telehealth visit, patients should gather: a printed copy of recent labs (lipid panel, CMP, TSH if hypothyroidism is suspected as a secondary cause of hyperlipidemia), a list of current medications and doses, and a summary of previous statin trials. A complete medication list reduces visit time and supports a faster prior authorization submission.

Labs Required Before Starting Praluent in Alabama

Four lab values are typically reviewed before a prescriber initiates alirocumab. None are absolute contraindications on their own, but they establish baseline cardiovascular risk and rule out secondary causes of hyperlipidemia.

A fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides) is the central requirement. Labs drawn non-fasting are acceptable for LDL-C estimation in most guidelines, but fasting labs are preferred when triglycerides are elevated, because elevated triglycerides artifactually lower the calculated LDL-C [9].

A basic metabolic panel (BMP) or comprehensive metabolic panel (CMP) provides liver function and renal function data. Alirocumab does not require dose adjustment for hepatic or renal impairment per the FDA prescribing information, but baseline values matter for monitoring [1].

Thyroid-stimulating hormone (TSH) is recommended when hypercholesterolemia is newly diagnosed or worsening, because untreated hypothyroidism is a reversible cause of elevated LDL-C that should be addressed before adding a PCSK9 inhibitor [4].

HbA1c or fasting glucose rounds out the metabolic picture. Statin therapy carries a small but documented risk of new-onset diabetes, and documenting baseline glycemic status protects both the patient and the prescriber.

The HealthRX clinical team uses a four-lab bundle (lipid panel, CMP, TSH, HbA1c) as the standard pre-authorization package for alirocumab candidates. Ordering all four in a single blood draw reduces patient burden and satisfies the documentation requirements of the major Alabama commercial payer PA forms simultaneously.

Prior Authorization Requirements in Alabama

Prior authorization is the central access barrier for most Alabama patients. Commercial payers in Alabama, including Blue Cross Blue Shield of Alabama, United Healthcare, Aetna, Cigna, and Humana, each maintain their own PA criteria, but common requirements are:

• A documented diagnosis of HeFH or ASCVD with ICD-10 coding (E78.01 for HeFH, I25.10 for ASCVD)
• LDL-C above payer-specific threshold despite maximally tolerated statin therapy (commonly above 70 mg/dL for ASCVD, above 100 mg/dL for HeFH)
• Documentation of trials of at least two statins at high-intensity doses or explanation of statin intolerance with supporting clinical notes
• A recent (within 6-12 months) lipid panel result
• Prescriber attestation that the patient is on a maximally tolerated lipid-lowering regimen

The 2022 ACC Expert Consensus Decision Pathway states that "PCSK9 inhibitors are appropriate in patients with ASCVD who have LDL-C at or above 70 mg/dL despite maximally tolerated statin therapy and ezetimibe" [6]. That language maps directly onto most commercial PA criteria and is worth quoting verbatim in appeal letters.

Alabama Medicaid does not cover Praluent for HeFH or established ASCVD as of the current formulary cycle. Patients on Medicaid should ask their prescriber about the manufacturer's patient assistance program (Praluent PAP through Sanofi) and the Praluent $0 copay card for eligible commercially insured patients.

Who Can Prescribe Praluent in Alabama

Any licensed prescriber with Schedule authority in Alabama may prescribe Praluent because alirocumab is not a controlled substance. That means:

Physicians (MD and DO) licensed by the Alabama Board of Medical Examiners hold full prescribing authority with no restrictions [7].

Certified registered nurse practitioners (CRNPs) in Alabama operate under a collaborative practice agreement with a supervising physician per Alabama Code Section 34-21-86. A CRNP may prescribe Praluent under that agreement, and many telehealth platforms in Alabama use CRNPs as the primary prescriber with physician oversight built into the platform's protocols.

Physician assistants (PAs) in Alabama also prescribe under a supervising physician agreement per the Alabama Physician Assistants Act. A PA working in a cardiology or primary care practice may prescribe alirocumab within the scope of that collaboration.

The practical takeaway: patients do not need to see a cardiologist specifically. A primary care PA or NP at a telehealth platform licensed in Alabama can initiate Praluent prescribing after a thorough clinical evaluation and within the bounds of their supervisory agreement.

Pharmacy Options: Specialty, Retail, and 503A Compounding

Specialty pharmacy. Praluent is classified as a specialty medication and is dispensed almost exclusively through specialty pharmacies. The primary specialty pharmacies servicing Alabama patients are CVS Specialty, Walgreens Specialty, Accredo (Express Scripts), and Optum Specialty. These pharmacies ship cold-packaged Praluent with temperature-monitored packaging directly to the patient's door. Alabama has no restriction on specialty pharmacy shipment of alirocumab across county lines within the state.

Retail pharmacy. Select retail pharmacy locations with specialty dispensing capabilities can fill Praluent. Patients should call ahead to confirm stock and cold-chain handling before requesting a retail fill.

503A compounding pharmacies in Alabama. State-licensed 503A compounding pharmacies in Alabama are legally permitted to prepare alirocumab for individual patients when a valid prescriber-patient relationship and a prescription exist. Compounded alirocumab may be an option for patients who cannot access commercial Praluent due to prior authorization denials or cost barriers. The compounded product is not FDA-approved, and patients should confirm that any 503A pharmacy they use holds a current Alabama State Board of Pharmacy license [10]. The FDA distinguishes between 503A pharmacies (patient-specific compounding) and 503B outsourcing facilities (larger-scale production); most Alabama-based compounding pharmacies operate under 503A status [10].

Patients who transfer an existing Praluent prescription from another state to an Alabama specialty pharmacy should contact the specialty pharmacy's transfer team directly. The new Alabama-licensed specialty pharmacy will request the prescription from the original dispensing pharmacy and verify active prior authorization with the patient's insurer before releasing the first Alabama fill.

The Clinical Evidence Supporting Alirocumab

The strongest evidence for alirocumab in cardiovascular risk reduction comes from ODYSSEY OUTCOMES (N=18,924), published in the New England Journal of Medicine in 2018 [11]. The trial enrolled patients with a recent acute coronary syndrome (ACS) event and randomized them to alirocumab 75 mg every two weeks (with uptitration to 150 mg) or placebo on top of high-intensity statin therapy. At a median follow-up of 2.8 years, alirocumab reduced the primary composite endpoint (coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization) by 15% relative risk reduction (hazard ratio 0.85; 95% CI 0.78-0.93; P<0.001) [11].

The number needed to treat (NNT) to prevent one primary event over 3 years was 54 in the overall trial population, falling to 16 in patients with baseline LDL-C at or above 100 mg/dL [11]. That NNT-16 subgroup is clinically meaningful and represents exactly the high-risk patients most likely to present in an Alabama cardiology practice.

In ODYSSEY LONG TERM (N=2,341), alirocumab 150 mg every two weeks reduced LDL-C by a mean of 61% at 24 weeks [3]. Serious adverse events were similar between alirocumab and placebo groups. Injection-site reactions occurred in 7.2% of alirocumab patients versus 5.1% in placebo patients, but discontinuations due to adverse events were uncommon.

The 2019 ESC/EAS Guidelines for Dyslipidaemia state that "PCSK9 inhibitors are recommended in very-high-risk patients not reaching goals with maximally tolerated statin therapy plus ezetimibe" [12]. That recommendation carries a Class I, Level of Evidence A designation. The 2018 AHA/ACC Guideline on the Management of Blood Cholesterol gives a Class IIa recommendation for PCSK9 inhibitors in very-high-risk ASCVD patients with LDL-C at or above 70 mg/dL despite maximally tolerated statins and ezetimibe [4].

A 2022 meta-analysis of PCSK9 inhibitor trials (N=67,237 total participants across alirocumab and evolocumab trials) published in The Lancet confirmed a consistent 1.5% absolute risk reduction in major adverse cardiovascular events per 1 mmol/L (38.7 mg/dL) reduction in LDL-C [13]. The relationship was linear down to LDL-C levels below 20 mg/dL, supporting aggressive LDL-C lowering in highest-risk patients.

Transferring a Praluent Prescription to Alabama

Patients who relocate to Alabama and already take Praluent in another state need to re-establish the prescription with an Alabama-licensed prescriber. Federal law does not allow specialty pharmacies to honor out-of-state controlled-substance prescriptions across state lines; while Praluent is not a controlled substance, most specialty pharmacies require an active relationship with an Alabama-licensed prescriber for ongoing specialty medication management.

The transfer process typically takes 3-10 business days and involves three steps: confirming with your new Alabama prescriber that they will continue therapy, having them submit a new prescription and updated prior authorization to your specialty pharmacy, and notifying your insurer's specialty pharmacy of the prescriber change to avoid a coverage interruption.

If your prior authorization was issued in another state, it may not transfer automatically. Alabama commercial payers will generally require a fresh PA submission linked to an Alabama-licensed prescriber. Starting that PA process at least 30 days before your supply runs out is advisable to prevent a gap in therapy.

Cost and Patient Assistance

The list price of Praluent is approximately $6,600 per year before insurance discounts. Most commercially insured patients who obtain prior authorization pay between $0 and $60 per month with manufacturer copay support.

Sanofi's Praluent patient assistance program provides free drug to eligible uninsured and underinsured patients who meet income criteria. The Praluent $0 copay card reduces out-of-pocket costs to $0 per month for eligible commercially insured patients; patients can enroll at the manufacturer's patient support portal or ask their specialty pharmacy to initiate enrollment. Alabama Medicaid patients are not eligible for the copay card but may qualify for the free drug program depending on household income.